BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.
RootPath Genomics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in developing a personalized T-cell therapy platform that integrates precision medicine with cancer immunotherapy. The company's innovative technologies focus on the analysis and manipulation of individual immune cells, enabling advancements in immune and cell therapy. By precisely monitoring and modulating the immune system, RootPath aims to enhance the diagnosis and treatment of cancer, contributing to significant improvements in patient outcomes.
Shanhai Innovation
Series C in 2025
Shanhai Innovation is a biological development company focused on supramolecular science and technology research and development. It provides supramolecular material, organic liquid, ionic salt, and biocatalysis. It serves biomedicine, daily cosmetics, health food, medical equipment, and food additives.
Hengyu Medical
Venture Round in 2025
Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment.
Degron Therapeutics
Series A in 2025
Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.
MyoGene Life Sciences
Series A in 2025
MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
AusperBio
Series B in 2024
AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, the company aims to enhance targeted delivery technologies to improve treatment outcomes. AusperBio is dedicated to addressing a variety of diseases, including viral infections, genetic disorders, metabolic conditions, and immune diseases, through its small interfering ribonucleic acid (siRNA) drugs. By concentrating on effective treatment strategies and vaccination for chronic hepatitis B, AusperBio seeks to provide patients with improved therapeutic options and protection against this challenging disease.
Yili Pharmaceutical
Seed Round in 2024
Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Allink Biotherapeutics
Series A in 2024
Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.
Macrolux Medical
Series B in 2024
MacroLux is a medical technology company that specializes in endoscopic interventional solutions for diagnosis and treatment. The company focuses on developing devices that enhance the detection and treatment of conditions in urology, respiratory, and digestive health. By offering advanced endoscopic therapies, MacroLux aims to improve patient outcomes through earlier diagnosis and more effective treatment options, catering to a wide range of medical customers.
Youzhong New Material Technology
Series A in 2024
Youzhong New Materials is a micro-nano device R&D company that designs, develops, and manufactures micro-nano devices using nanoimprint core technology.
Secretech
Seed Round in 2024
Secretech is a biotechnology company focused on research and development, specializing in the creation of biomarkers and cellular exosomes. The company develops a molecular detection technology platform designed to serve the scientific, clinical, and drug discovery sectors. Secretech is dedicated to advancing a new generation of molecular detection methods, integrating sophisticated computational biology algorithms to enhance proteomics analysis. This innovative approach aims to accelerate the discovery of new molecular markers, providing valuable tools for researchers and clinicians in their pursuit of medical advancements.
Chuanxin Biotech
Venture Round in 2024
Chuanxin Biotech is an RNA drug research and development service provider.
Changsha Morning Shine
Series A in 2023
Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services.
Shenzhen CardioACC
Seed Round in 2023
Shenzhen CardioACC Ltd specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.
KeChow Pharma
Funding Round in 2023
Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.
Gachun Biotech
Series A in 2023
Gachun Biotech is a pharmaceutical intermediates industrialization platform that focuses on APIs, or pharmaceutical intermediates.
Huili Pharmaceutical
Series A in 2023
Huili Pharmaceutical is a drug delivery platform that specializes in the development of nanoparticles and microsphere preparation equipment.
Shennapsi Artificial Intelligence Technology
Series A in 2023
Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterol monitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
Essentia Biosciences
Angel Round in 2023
Essentia Biosciences is a biotechnology company that specializes in the development of cells, gene technology drugs, and medical devices.
Gene Cradle
Series B in 2023
Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.
Jiamuyao Medical
Seed Round in 2023
Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.
Xiguang Bio
Series B in 2023
Xiguang Bio focuses on the production of diagnostic reagents and provides chemiluminescent raw materials and overall system technology solutions.
Beyond Therapeutics
Seed Round in 2023
Beyond Therapeutics employs its ExCEED technology to speed the discovery and development of novel medications for unmet therapeutic needs.
Panomic Biomedical Technology
Series A in 2023
Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.
Chromai
Venture Round in 2023
Chromai specializes in high-performance intelligent liquid chromatography and medical diagnostic solutions, focusing on simplifying the diagnostic and testing processes. The company employs advanced technologies such as artificial intelligence, Big Data, and the Internet of Things, integrating these with leading analysis and detection methods. Chromai is dedicated to enhancing the fields of health in vitro diagnostics, environmental protection, and scientific instruments. Committed to independent innovation, the company aims to contribute to the revitalization of national industry while providing efficient diagnostic and testing analysis for medical users.
XellSmart
Series A in 2023
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Ruoyi Biotech
Seed Round in 2023
Ruoyi Biotech is a developer of macromolecular drug delivery technology.
Innovision
Series A in 2023
Innovision develops auxiliary diagnosis and treatment systems tailored for endoscopy centers in hospitals. The company utilizes artificial intelligence and deep learning technologies to enhance the medical imaging-assisted diagnosis of the digestive system. By processing digestive endoscopy image data, Innovision's systems aim to improve operational efficiency in hospitals, alleviating the workload of endoscopy doctors and minimizing the need for additional medical personnel. This approach supports healthcare providers in delivering better patient care while streamlining their clinical processes.
Chime Biologics
Series B in 2023
Chime Biologics Limited is a Contract Development and Manufacturing Organization (CDMO) based in Wuhan, China, established in 2013. The company specializes in providing a comprehensive range of biopharmaceutical development and manufacturing services, including drug substance and drug product manufacturing, cell line development, and protein science characterization. Chime Biologics also offers technical transfer, regulatory support, and project management services to meet the needs of the biopharmaceutical industry. The organization supports clients through all stages of development, from early drug development to late-stage clinical trials and commercial production, ensuring compliance with cGMP standards. By delivering customer-centric and cost-effective solutions, Chime Biologics aims to enhance access to affordable medicines and improve patient care.
Power Site
Series B in 2023
Power Site is a modern technology enterprise that supplies X-ray imaging core components. It mainly provides high-voltage generators (HVG), combined X-ray sources, power distribution units (PDU), and other core components overall solutions for X-ray imaging systems. The products are mainly used in high-end X-ray imaging systems such as CT, DR, mammography, C-arm, CBCT, security inspection, industrial inspection, etc. The company has an advanced and efficient manufacturing platform with an annual production capacity of 50,000 units.
Yike Polymers
Series B in 2023
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Human Zhizao
Series A in 2023
Human Zhizao is a technology platform that provides comprehensive diagnostic solutions. They provide clinical customers with a parallel, full-automatic multiple flow cytometry fluorescence detection platform and supporting reagents. They provide customer service. The flow fluorescence luminescence technology is a new generation of throughput detection and analysis platform integrating flow analysis, laser analysis, digital signal processing, and other technologies. They involve projects that require the joint detection of multiple indicators, such as autoantibodies, allergens, cytokines, etc.
Lealing Biotech
Venture Round in 2023
Lealing Biotech developes anti-body based drugs and pharmaceutical products.
ProxyBio
Venture Round in 2023
ProxyBio develops treatment and pharmaceutical products for mRNA development.
Hanchao Pharmaceutical
Venture Round in 2023
Hanchao Pharmaceuticals is a biopharmaceutical manufacturer that develops medicines and other medical equipment.
Yangqi Intelligent
Angel Round in 2022
Yangqi Intelligent provides answers for medical equipment. It provides goods like qise, elixir, wonder vision, odd control, and more. A self-made radiation body surface monitoring camera is called wonder vision. Qice is a platform for artificial intelligence-based medical models. Sales.
Pulnovo Medical
Venture Round in 2022
Pulnovo Medical, founded in 2013 in Wuxi, Anhui, specializes in the development, production, and service of innovative medical devices aimed at treating pulmonary hypertension. The company focuses on advanced pulse radiofrequency ablation technology, which includes pioneering high-frequency ablation equipment and intravascular catheters. These products are designed to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure, offering a novel approach to treatment with a commitment to improving patient outcomes. Pulnovo Medical holds global invention patents for its unique technologies, underscoring its role as a leader in this specialized medical field.
NeuShen Therapeutics
Seed Round in 2022
NeuShen Therapeutics is a biotechnology company focused on developing innovative therapies for neurological and psychiatric disorders. Utilizing a small molecule pipeline and an adeno-associated virus (AAV) gene therapy platform, the company aims to create effective medical solutions for mental illnesses. NeuShen Therapeutics is dedicated to providing patients with treatments that offer both cures and relief from their conditions.
Cell Probio
Series B in 2022
Cell Probio is a manufacturer of cell culture consumables, positioned in the R&D, production and sales of high-end biological consumables.
Palline Data
Series A in 2022
Palline is a company that specializes in hospital management solutions and operational data analysis. It leverages data to encourage hospital management to implement lean practices and enhance the allocation of medical resources through strategic adjustments. By employing statistical methods and artificial intelligence, Palline develops mathematical models for performance evaluation and incentive system construction. This enables hospital operators to conduct strategy analysis and quantitative evaluations more efficiently. The company offers comprehensive solutions that encompass management concepts, tools, big data applications, and software systems, all aimed at optimizing hospital operations and resource allocation.
Zhongguancun Shuimu Medical Technology
Series A in 2022
Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.
Joymed Technology
Series B in 2022
Joymed Technology specializes in the research and development, registration, and manufacturing of medical devices, providing comprehensive solutions tailored for medical equipment businesses. The company focuses on delivering innovative and reliable technology while ensuring high-quality standards in its products. By offering services such as device design, risk management, marketing, and product verification and validation, Joymed Technology enables its clients to develop and launch safe and affordable medical products efficiently. The company aims to become a trusted partner for both domestic and international medical device firms, particularly assisting small and medium-sized enterprises in navigating the complexities of the medical product market. Through flexible collaboration and optimized design processes, Joymed Technology seeks to accelerate mutual growth with its customers.
Future Vision
Series B in 2022
Future Vision is a visual health service organization based in Shanghai, specializing in the prevention and control of myopia, amblyopia rehabilitation training, and medical optometry for children aged 3 to 16. The company utilizes advanced North American optometry technology to deliver its services, aiming to address the growing concerns of visual health among children. By focusing on early intervention and comprehensive eye care, Future Vision seeks to improve the visual outcomes for its young clientele.
Ehomepoct
Series C in 2022
Ehomepoct is a healthcare management company based in Changsha, China, specializing in the manufacture of diagnostic test kits. The company produces a range of products, including pregnancy tests, inflammation tests, and menstrual period tests, as well as early embryo testing. Ehomepoct also focuses on integrating artificial intelligence into medical treatment applications, enhancing rapid diagnosis and health management services.
Degron Therapeutics
Series A in 2022
Degron Therapeutics is a drug discovery platform focused on developing a new class of targeted protein degradation therapeutics, specifically small molecule molecular glue degrader drugs. The company aims to become a leader in the discovery and development of these innovative medicines, which target disease mechanisms that are often inaccessible to traditional small molecule inhibitors. By leveraging its advanced molecular glue protein degradation platform technology, Degron Therapeutics identifies and validates disease targets while creating novel selective compounds. This approach addresses significant unmet medical needs across various therapeutic areas. The company boasts a team of experienced executives and scientific leaders dedicated to enhancing treatment efficiency through its drug development initiatives.
SiranBio
Angel Round in 2022
SiranBio is a biotechnology that develops innovative siRNA drugs.
AccuPulse
Series A in 2022
AccuPulse is focused on the development of a pulsed electric field ablation (PFA) system designed to treat atrial fibrillation (A-fib). The company offers a comprehensive solution that includes both a PFA generator and specialized catheters for the pulse ablation of A-fib and tumors. By integrating advanced technologies, AccuPulse aims to enhance catheter localization and signal acquisition, while also improving the overall efficiency of interventional therapies that utilize radio frequency and cryotherapy. This innovative approach seeks to provide healthcare professionals and patients with a more effective and intelligent treatment option for managing A-fib and related conditions.
Resproly
Series B in 2022
Resproly is a company engaged in the research, development, production, and sales of formulations and equipment for respiratory inhalation. It operates as an integrated enterprise, concentrating on multiple clinically significant treatment areas, including asthma, chronic obstructive pulmonary disease (COPD), diabetes, and Parkinson's disease. By focusing on inhaled formulations and advanced pulmonary drug delivery technology, Resproly aims to address the therapeutic needs associated with these conditions, contributing to improved patient outcomes in respiratory health.
NeuroEchos
Series A in 2022
NeuroEchos, established in August 2017, specializes in functional neurosurgery by offering integrated diagnosis and treatment solutions for conditions linked to abnormal nervous system activity. The company utilizes advanced artificial intelligence to assist in diagnosing and interpreting electroencephalogram (EEG) waves, enhancing the accuracy of neurological assessments. Additionally, NeuroEchos supports neuroscience research through the development and provision of deep brain electrodes, contributing to a better understanding of neurological disorders and improving patient outcomes.
Baikuirui
Seed Round in 2022
Biocreatech is a biotechnology firm that uses protein design and synthetic biology to create cell factories capable of producing a range of products such as drug intermediates, fine chemicals, functional peptides, and therapeutic proteins. They involve in integrating multiple proteins into molecular machines in order to transform cells into factories.
Enzymaster
Series C in 2022
Enzymaster (Ningbo) Bio-Engineering Co., Ltd. specializes in the development and commercialization of innovative enzyme technologies and biocatalytic synthesis for various industries, including pharmaceuticals, food, and environmental applications. Founded in 2013 and based in Ningbo, China, the company produces a range of products, such as L-tert-leucine and D-Calcium Pantothenate, aimed at enhancing the production of active pharmaceutical ingredients, fine chemicals, and consumer goods. Enzymaster is committed to sustainable practices and focuses on environmentally friendly manufacturing through enzyme-directed evolution and strain engineering. By advancing these technologies, the company seeks to improve both societal and environmental outcomes while promoting safer manufacturing processes.
Farber Xintian
Seed Round in 2022
Farber Xintian CRO company engaged in clinical services of radionuclide drugs. The company focuses on the field of nuclide drugs. Through cooperation with domestic experts in the field of nuclide drugs, the company introduces IP and relies on its own resource advantages to create a VIC model for domestic nuclide drugs.
Junsai Shengwu
Series A in 2022
Junsai Shengwu developes therapies for new solid tumor cell.
Juncell Therapeutics
Series A in 2022
Juncell Therapeutics focuses on developing innovative therapies and pharmaceutical drugs specifically for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are subsequently developed outside the human body and re-injected into patients, allowing for targeted treatment of tumors. This approach aims to enhance the effectiveness of cancer therapies while minimizing side effects, ultimately improving patient outcomes in the fight against cancer.
Shengshi Technology
Seed Round in 2022
Shengshi Technology is a specialized platform focused on experimental simulation using computational fluid dynamics (CFD) and artificial intelligence for medical engineering research, particularly related to cardiovascular diseases. The company develops non-invasive precision diagnostic and treatment solutions, leveraging advanced technologies such as external fluid dynamics experimental simulation and CFD numerical simulation. By integrating these key technologies, Shengshi Technology aims to enhance the quality of healthcare services for both doctors and patients, ultimately improving outcomes in the management of cardiovascular conditions.
InnoBM Pharmaceuticals
Venture Round in 2022
InnoBM Pharmaceuticals is engaged in the manufacturing of biomaterials and pharmaceutical products. The company focuses on developing novel therapeutics aimed at enhancing the efficacy of tumor immunotherapy. By prioritizing innovation, InnoBM Pharmaceuticals is dedicated to delivering advanced treatment options for cancer patients, thereby contributing to the improvement of cancer care and patient outcomes.
Guangwei Pharmaceuticals
Venture Round in 2022
Guangwei Pharmaceuticals is a pharmaceutical manufacturer in China that produce medical theater products.
Yuanjingtaico
Seed Round in 2021
Yuanjingtaico is a biotech firm focused on the R&D of fluorescent PCR reagents, microfluidic, and electrochemical detection products.
KingstronBio
Series C in 2021
KingstronBio specializes in the development and manufacturing of advanced heart valve products for cardiac surgeries. The company offers a comprehensive range of biological heart valves, focusing on minimally invasive solutions that enhance patient outcomes. Utilizing cutting-edge technologies, including anti-calcification, dry presentation, and leaflet thinning, KingstronBio aims to deliver innovative and effective products to the medical community, thereby addressing critical needs in cardiovascular care.
Lingtai Biotechnology
Seed Round in 2021
Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.
Changmugu Medical
Series B in 2021
Beijing Changmugu Medical Technology Co., Ltd. is a healthcare startup specializing in artificial intelligence-powered solutions for orthopedic surgery. The company focuses on enhancing the accuracy and safety of surgical procedures through advanced technologies, including AI-assisted diagnosis and individualized operation plans. Additionally, it offers 3D printing patient-specific instrumentation (PSI) for surgical navigation and post-operative intelligent evaluation services. By leveraging AI deep learning, Changmugu Medical aims to provide innovative tools that improve patient outcomes and streamline surgical processes, ultimately contributing to safer and more stable operations in the field of orthopedics.
Comma Bio
Series A in 2021
Comma Bio is a comprehensive solution provider for sample pretreatment. Based on two types of snap-neck material technologies of adsorption and separation materials and filter materials, the company has created three major technology platforms for porous plastics, separation materials and precision injection molding. Customers in the fields of, precision medicine, analysis and testing provide comprehensive solutions for sample pre-processing.
Tripod Preclinical Research
Venture Round in 2021
Tripod Preclinical Research is a Contract Research Organization that specializes in providing preclinical research services to the biopharmaceutical and medical device industries. The company offers a comprehensive range of services, including drug safety evaluation for new chemical entities, food additives, biologics, pesticides, veterinary drugs, and cosmetics. Tripod's expertise encompasses non-human primate disease models, pharmacological efficacy studies, early drug evaluation, and Good Laboratory Practices (GLP) toxicology. Additionally, the organization supports translational medicine and clinical trials, along with biological analysis and the management of biological sample banks. By delivering these services, Tripod aids drug developers and researchers in advancing their projects through the critical early stages of research and development.
Hopstem
Series B in 2021
Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.
Bioligo
Series A in 2021
Bioligo, officially known as Shanghai Bailige Biotechnology Co., Ltd., is a biotechnology company specializing in the provision of high-quality DNA synthesis and sequencing services. The company integrates research and development, production, and professional management to cater to the needs of the in vitro diagnostic industry. Bioligo primarily serves downstream customers in the genetic and molecular diagnostics sectors, which are integral to precision medicine. Its product offerings include a variety of DNA primers, fluorescently labeled probes, adapters, blocking agents, amplicon primers, and target capture probes essential for next-generation sequencing (NGS) library construction. Additionally, Bioligo provides large-scale RNA and DNA synthesis services, addressing critical supply gaps for its customers in the diagnostics field.
Guangzhou Creative Biosciences
Series D in 2021
Creative Biosciences is a biomedical technology company focused on developing and producing diagnostic products for tumor screening, particularly in the realm of colorectal cancer. The company specializes in fecal DNA detection technology, providing non-invasive screening kits that allow medical practitioners to accurately identify genetic abnormalities in fecal samples. These diagnostic tools are designed to aid in the early detection of intestinal cancer lesions, thereby supporting healthcare professionals and researchers in their efforts to improve cancer treatment outcomes. Through its innovative approach, Creative Biosciences aims to enhance cancer screening processes and contribute to better patient care.
Boan Biotech
Series B in 2021
Boan Biotech is a fully integrated biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutic antibodies. The company focuses on several key therapeutic areas, including oncology, metabolism, autoimmunity, and ophthalmology. While it primarily generates revenue from customers in Mainland China, Boan Biotech aims to expand its reach globally. The company is committed to delivering high-quality biologics to address unmet medical needs in these critical fields.
Vision X
Series B in 2021
Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.
Reforgene Medicine
Series A in 2021
Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic diseases, and cancer. Utilizing advanced gene editing and genomic technologies, the company works on creating programmable medicine that enhances treatment options for patients. By leveraging these cutting-edge techniques, Reforgene Medicine strives to improve patient outcomes and provide effective solutions for complex health challenges.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for renal diseases and related chronic conditions. The company specializes in the research, development, regulatory approval, and commercialization of medicines aimed at treating various kidney diseases, including chronic kidney disease, complications associated with dialysis, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified and balanced pipeline of drug candidates, Alebund Pharmaceuticals aims to provide comprehensive and high-quality solutions for patients suffering from renal diseases.
NeuExcell Therapeutics
Seed Round in 2021
NeuExcell Therapeutics is an early-stage gene therapy company dedicated to addressing neurodegenerative diseases and neural injuries. The company has developed a novel neural repair technology that employs in vivo astrocyte-to-neuron conversion. By introducing neural transcription factors through adeno-associated virus-based gene therapy, NeuExcell aims to restore damaged neural tissue. This innovative approach seeks to improve the quality of life for millions of patients worldwide suffering from various neurodegenerative conditions.
Hopstem
Series A in 2021
Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.
IntoCare
Series D in 2021
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
Panomic Biomedical Technology
Series A in 2021
Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.
Next Generation Gene Therapeutics
Series A in 2021
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.
Brattea
Series B in 2021
Brattea is a medical device research and development company specializing in renal denervation products aimed at treating conditions such as hypertension, cancer pain, and diabetes. The company develops interventional devices, including renal artery ablation catheters and radiofrequency ablation equipment, as well as medical mapping systems. These products are designed to address a range of health issues, including refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Brattea is committed to providing reliable medical solutions that enhance patient care and improve health outcomes.
Synaptic Medical
Series G in 2021
Synaptic Medical Inc. is a medical device company that develops and commercializes products aimed at treating cardiac arrhythmias and other cardiovascular diseases. Founded in 2005, the company operates from its headquarters in St. Paul, Minnesota, and has an additional office in Beijing, China. Synaptic Medical specializes in cardiac electrophysiology products, including bipolar pacing systems, fixed curve and deflectable diagnostic catheters, pulmonary vein mapping catheters, and ablation technologies. The company's mission is to create innovative, cost-effective, and clinically advanced solutions that enhance treatment options for physicians and their patients.
Tavotek Biotherapeutics
Series A in 2021
Tavotek Biotherapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutic medicines for patients with severe diseases that lack effective treatments. The company is led by experienced pharmaceutical executives who have successfully developed numerous biologics currently on the market. Tavotek employs three distinct research and development platforms: TavoSelect, an innovative Phage Display Library; TavoPrecise, an engineering platform for tissue-specific biologics; and TavoMIP, a multicyclic peptide platform. This diverse array of technologies supports Tavotek's extensive pipeline of product candidates, which targets cancers, autoimmune disorders, and infectious diseases, thereby addressing significant unmet medical needs in the healthcare landscape.
Pro-Heal
Seed Round in 2021
Pro-Heal Pharmaceuticals is a biotechnology company specializing in the development of pharmaceutical products, particularly for ophthalmic and autoimmune diseases. The company is dedicated to creating biological macromolecule drugs and ophthalmology medicines that address urgent clinical needs, offering innovative solutions for patients who lack access to effective treatments. By focusing on these critical areas, Pro-Heal aims to advance healthcare outcomes and provide essential therapies that are currently unavailable in the market.
Changmugu Medical
Venture Round in 2021
Beijing Changmugu Medical Technology Co., Ltd. is a healthcare startup specializing in artificial intelligence-powered solutions for orthopedic surgery. The company focuses on enhancing the accuracy and safety of surgical procedures through advanced technologies, including AI-assisted diagnosis and individualized operation plans. Additionally, it offers 3D printing patient-specific instrumentation (PSI) for surgical navigation and post-operative intelligent evaluation services. By leveraging AI deep learning, Changmugu Medical aims to provide innovative tools that improve patient outcomes and streamline surgical processes, ultimately contributing to safer and more stable operations in the field of orthopedics.
KYinno
Series A in 2021
KYinno is a drug development company that is dedicated to oncology drug development with a focus on immune treatments against cancer.
HuiKai
Series A in 2021
HuiKai Medical focuses on the research and development, as well as the manufacturing of medical devices tailored for the urinary system. The company's product range addresses various urological conditions, including prostatic hyperplasia, urinary stones, urinary incontinence, and urological tumors. By employing proprietary technology and innovative materials, HuiKai Medical aims to enhance patient comfort and streamline procedures, thereby improving overall healthcare efficiency and outcomes.
VesiCURE
Venture Round in 2021
VesiCURE Therapeutics is a company dedicated to the research and development of innovative exosome-based drugs. Founded in 2021 and located in Suzhou, Jiangsu, China, VesiCURE aims to advance the exosomal pharmaceutical industry by focusing on the creation and enhancement of exosomal therapies. The company's efforts are centered on harnessing extracellular vesicles to develop new drug formulations, thereby contributing to the evolution of this emerging sector in medicine.
PegBio
Private Equity Round in 2020
Founded in 2008 and based in Suzhou, PegBio is a biopharmaceutical company focused on developing innovative treatments for diabetes and obesity. The company's flagship product, PB-119, is a glucagon-like peptide 1 (GLP-1) agonist designed to improve the management of diabetes by allowing patients to take medication once a week, in contrast to the daily injections typically required. PegBio's research extends beyond diabetes, encompassing areas such as nonalcoholic fatty liver disease, gout, cardiovascular conditions, and cancer. The company aims to address significant health challenges through its advanced drug discovery efforts.
OMNI
Series C in 2020
Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.
Yingsheng Biology
Series B in 2020
Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development and production of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, and metabolic disorders. The company offers a diverse range of products, including 45 innovative genetic metabolic disease screening reagents, deaf genetic testing kits, and HLA-B27 detection kits. These products aim to facilitate early detection of genetic conditions and birth defects, promoting timely intervention and disease prevention. Yingsheng Bio utilizes advanced molecular diagnostic techniques and sophisticated detection systems, contributing significantly to the fields of human genetics and public health.
Genskey
Series C in 2020
GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. Utilizing high-throughput sequencing technology and intelligent algorithm analysis, GensKey addresses traditional challenges such as low detection rates, lengthy processes, and diagnostic accuracy. This innovative approach allows for timely and precise diagnoses for patients suffering from severe infections, ultimately improving patient outcomes by facilitating quicker access to appropriate medical interventions.
Zylox Medical Device
Series C in 2020
Zylox Medical Device Co. was established in 2012 in Hangzhou by a team of experienced professionals who returned to China after working in prominent medical device companies in the US and Europe. The company specializes in developing innovative interventional and implantable devices for peripheral and neurovascular applications. Its product portfolio includes a range of devices such as PTA balloons, drug-coated PTA balloons, stents, and thrombectomy devices. Zylox is committed to providing high-quality medical solutions aimed at improving patient care and enhancing the capabilities of healthcare professionals. The company continues to expand its product offerings to address various vascular conditions both in China and internationally.
Delta Medical
Series D in 2020
Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.
X-ABT is a tech enterprise that provides solutions for pathogenic microorganism detection in the medical and health fields. The company focuses on providing complete solutions for the detection of infectious pathogens in the medical and health field. They develop and produce systems for disease control, prevention, clinical hospitals, and entry-exit customs. X-ABT also provides clinical marketing and sales services to help medical workers and serve patients.
Borayer
Series B in 2020
Borayer is engaged in the development and production of biological materials aimed at clinical medicine. The company specializes in biotechnology to create consumables for wound repair, including products that facilitate rapid hemostasis, wound adhesion, and guided tissue regeneration. By focusing on these areas, Borayer aims to enhance clinical medical products and technologies, ultimately improving patient outcomes in the field of wound management and repair.
IntoCare
Series C in 2020
IntoCare is a high-tech company specializing in surgical products such as "Smart" powered staplers.
AIVFO
Venture Round in 2020
AIVFO produces full-line culture fluids and intelligent automation equipment.
Bioheart
Series B in 2019
Shanghai Bioheart Biotechnology Co., Ltd., established in 2014 and located in Shanghai, China, specializes in the development of drug-eluting stents. The company is focused on creating innovative, high-value minimally invasive therapeutic products. Bioheart aims to enhance medical technology and provide superior healthcare solutions for medical professionals and patients alike, positioning itself as a significant player in the medical and healthcare industry.
Dami&Xiaomi
Series B in 2019
Shenzhen Dami He Xiaomi Cultural Broadcast Co., Ltd., known as Dami & Xiaomi, operates an online platform dedicated to supporting children with autism spectrum disorders. Established in 2014 and based in Shenzhen, China, the company offers a range of integrated services including rehabilitation, educational support, parent training, online courses, and science information. Dami & Xiaomi aims to address the needs of children with developmental disorders, focusing on effective strategies to help them manage autism and promote healthy growth. Through its comprehensive platform, it provides essential resources to empower parents and caregivers in their efforts to support their children's development.
EOC Pharma Group
Series C in 2019
EOC Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. The company specializes in developing, manufacturing, and commercializing innovative oncology products, utilizing a licensing model to enhance its product pipeline. EOC partners with global biopharmaceutical firms to integrate their molecules into its local manufacturing and regulatory frameworks. The company currently has a pipeline of seven novel products, four of which have received Class I innovative drug approvals and are undergoing clinical studies in China. EOC operates an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City, and maintains offices in major cities, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team experienced in pharmaceutical research and development, EOC aims to position itself as a leader in oncology innovation within China.
Ruixun Biotech
Series A in 2019
Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.